PT-141 (Bremelanotide)

A melanocortin agonist that increases sexual desire by acting on the central nervous system rather than on blood flow.

Written by Anthivera EditorialPending medical review

Updated Regulatory status verified May 1, 2026

FDA-approved

Relevance for women

FDA-approved (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the strongest evidence-based peptide option in this category.

Where the evidence sits

Anthivera’s calibrated five-tier scale — what the strongest evidence on PT-141 (Bremelanotide) actually supports today.

  1. Preclinical
  2. Limited clinical
  3. Multiple human studies
  4. Phase 3
  5. FDA-approvedPT-141

FDA-approved: FDA-approved for the indication claimed.

Questions to bring to a consult

  1. 01What evidence is there for PT-141 (Bremelanotide) in women specifically — and does that include perimenopausal or postmenopausal cohorts?
  2. 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
  3. 03What baseline labs do you require before starting, and how often do you monitor?
  4. 04What are the realistic timelines and what does “not working for you” look like in practice?

Articles on PT-141 (Bremelanotide)

Providers that offer PT-141 (Bremelanotide)

See the full provider comparison for all peptides side by side.